Metronidazole Polpharma (Metronidazole)

Metronidazole enters susceptible microorganisms and is reduced in the low‑oxygen environment of anaerobes. This reduction creates nitro radical anions that bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, ultimately leading to cell death while sparing aerobic cells.

The dose of Metronidazole Polpharma is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals determine the appropriate dosage regimen and duration.

The pregnancy category for metronidazole is not definitively established. It should be used during pregnancy only when the potential benefit justifies any potential risk to the fetus, and under medical supervision. Breastfeeding mothers should consult a healthcare provider, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

Metronidazole is distinct from beta‑lactam antibiotics and macrolides because it specifically targets anaerobic organisms and certain protozoa. Compared with clindamycin, another anaerobic‑active agent, metronidazole often has a broader spectrum against protozoal infections and a lower risk of Clostridioides difficile overgrowth, though individual choice depends on susceptibility patterns and patient factors.

Metronidazole Polpharma should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct light. The product must be kept out of reach of children and handled according to standard aseptic techniques for intravenous solutions.

The medication is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a period of 30 to 60 minutes, with dosing adjusted to the infection type and patient characteristics as prescribed.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, and hepatic toxicity. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities, and therapy should be discontinued if any of these serious effects occur.

Metronidazole Polpharma is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in those who cannot abstain from alcohol during treatment due to the risk of a disulfiram‑like reaction.